Navigation Links
Are siRNA Pools Smart?

RT-PCR data were normalized with 18S rRNA real-time RT-PCR.


Comparing siRNA Pools and Single siRNAs: Experimental Design and Results

Quantitative, phenotypic assays were used to determine how well single siRNAs performed relative to siRNA pools. siRNAs targeting 59 kinases, along with positive and negative control siRNAs, were studied. Cell populations were transfected with three single siRNAs (siRNA #1, siRNA #2, or siRNA #3), all targeting the same gene, or a pool of the three siRNAs (siRNA #1 + siRNA #2 + siRNA #3). In the experiments described below, cell number was monitored three days post-transfection (Figure 3), or apoptosis was induced using etoposide one day after transfection, and caspase 3 activity was assayed three days post-transfection (Figure 4). All transfected cells were assayed on the same day using master mixes of dyes and substrates to minimize experimental variability in the studies.


[click here to enlarge]

Figure 3. Cell Proliferation--Single siRNAs vs. siRNA Pools. (A) Expression levels of 59 kinases were reduced in HeLa cells by transfection in 96 well plates of three individual kinase-specific siRNAs or a pool of the three siRNAs. All samples were performed in triplicate. To each well containing siPORT NeoFX Transfection Agent and either one of three siRNAs (30 nM) or the three pooled siRNAs (10 nM each), 8x103 HeLa cells were added in a process termed reverse transfection [2]. Three days post-transfection, the cells were assayed using alamar
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Custom and library siRNA for efficient gene silencing
2. Custom and library siRNA for efficient gene silencing
3. Cancer siRNA Oligo Set Version 1.0
4. Library siRNA
5. Custom siRNA Oligo Synthesis Service
6. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
7. Quantification of siRNA Silencing Efficiency Using the LightCycler System
8. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
9. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
10. siRNA transfection optimization with the Agilent 2100 bioanalyzer
11. siRNA Design Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Are siRNA Pools Smart

(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
Breaking Biology Technology:Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4
... Aug. 4 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), ... clinical trials announced today that the company has acquired the ... Ltd. The acquisition will be operated by OmniComm,s UK subsidiary, ... exceptional software is used to collect clinical trial data gathered ...
... molecule-sized pores are one step closer to replacing the ... of academic researchers is reporting. Writing this week ... membranes, ability to separate molecules in a mixture is ... processing (RTP). By heating the membranes from room temperature ...
... , , SAN FRANCISCO, Aug. ... positive drug sales/earnings and partnering and M&A deals. As a result, ... 6.5 percent, mirroring the Dow and Nasdaq, which closed the month ... for a July in years. , , Helping ...
Cached Biology Technology:OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 2Rapid heating prepares energy-saving zeolite for greater role in industrial separations 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 2Biotech Hot in July Driven by Positive Drug Data and Acquisitions 3Biotech Hot in July Driven by Positive Drug Data and Acquisitions 4Biotech Hot in July Driven by Positive Drug Data and Acquisitions 5
(Date:5/22/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... promotional pricing and making the Wocket generally available for $229 ... Head of Marketing said, "We,ve extended the opportunity to take ... May. To get your wocket at this special price, submit ... on June 1, you,ll receive a unique code that gives ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... at land-grant universities are a major source of ... industry. To prepare future employees for work in ... in nursery management and production, but availability of ... horticulture programs have contributed to a reduction in ...
... 2011 Dr. Daniel Von Hoff was presented this month ... in sequencing, or spelling out, the DNA of patients with ... advances the art of using the fully sequenced genomes of ... DNA, to help determine the best course of treatment. ...
... Mich. (March 17, 2011) In a ... so-called "orphan" nuclear receptor TR4, Van Andel Research Institute ... more direct role than was previously known in certain ... of the central nervous system. Scientists had previously ...
Cached Biology News:Integrating instructional multimedia in nursery management, production courses 2Dr. Daniel Von Hoff presented with top genomics award from Scripps 2Study indicates vitamin A plays key role in the human body 2
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
...
Biology Products: